BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 26652482)

  • 1. Design, synthesis and biological evaluation of pyrazolyl-nitroimidazole derivatives as potential EGFR/HER-2 kinase inhibitors.
    Tao XX; Duan YT; Chen LW; Tang DJ; Yang MR; Wang PF; Xu C; Zhu HL
    Bioorg Med Chem Lett; 2016 Jan; 26(2):677-683. PubMed ID: 26652482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of pyrazolyl-thiazolinone derivatives as potential EGFR and HER-2 kinase inhibitors.
    Qiu KM; Wang HH; Wang LM; Luo Y; Yang XH; Wang XM; Zhu HL
    Bioorg Med Chem; 2012 Mar; 20(6):2010-8. PubMed ID: 22361272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors.
    Lv PC; Zhou CF; Chen J; Liu PG; Wang KR; Mao WJ; Li HQ; Yang Y; Xiong J; Zhu HL
    Bioorg Med Chem; 2010 Jan; 18(1):314-9. PubMed ID: 19914835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, antiproliferative activity, molecular docking and cell cycle analysis of some novel (morpholinosulfonyl) isatins with potential EGFR inhibitory activity.
    Ammar YA; Sh El-Sharief AM; Belal A; Abbas SY; Mohamed YA; Mehany ABM; Ragab A
    Eur J Med Chem; 2018 Aug; 156():918-932. PubMed ID: 30096580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
    Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
    Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, biological evaluation, and molecular docking studies of novel 2-styryl-5-nitroimidazole derivatives containing 1,4-benzodioxan moiety as FAK inhibitors with anticancer activity.
    Duan YT; Yao YF; Huang W; Makawana JA; Teraiya SB; Thumar NJ; Tang DJ; Tao XX; Wang ZC; Jiang AQ; Zhu HL
    Bioorg Med Chem; 2014 Jun; 22(11):2947-54. PubMed ID: 24792811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schiff's base derivatives bearing nitroimidazole and quinoline nuclei: new class of anticancer agents and potential EGFR tyrosine kinase inhibitors.
    Makawana JA; Sangani CB; Lin L; Zhu HL
    Bioorg Med Chem Lett; 2014 Apr; 24(7):1734-6. PubMed ID: 24630412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors.
    Tu Y; Wang C; Xu S; Lan Z; Li W; Han J; Zhou Y; Zheng P; Zhu W
    Bioorg Med Chem; 2017 Jun; 25(12):3148-3157. PubMed ID: 28428040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and molecular modeling of biquinoline-pyridine hybrids as a new class of potential EGFR and HER-2 kinase inhibitors.
    Sangani CB; Makawana JA; Duan YT; Yin Y; Teraiya SB; Thumar NJ; Zhu HL
    Bioorg Med Chem Lett; 2014 Sep; 24(18):4472-4476. PubMed ID: 25172421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.
    Wang SF; Zhu YL; Zhu PT; Makawana JA; Zhang YL; Zhao MY; Lv PC; Zhu HL
    Bioorg Med Chem; 2014 Nov; 22(21):6201-8. PubMed ID: 25267006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schiff's base derivatives bearing nitroimidazole moiety: new class of antibacterial, anticancer agents and potential EGFR tyrosine kinase inhibitors.
    Makawana JA; Sun J; Zhu HL
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6264-8. PubMed ID: 24144854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, biological evaluation and 3D QSAR studies of novel dioxin-containing pyrazoline derivatives with thiourea skeleton as selective HER-2 inhibitors.
    Yang B; Yang YS; Yang N; Li G; Zhu HL
    Sci Rep; 2016 Jun; 6():27571. PubMed ID: 27273260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives containing benzodioxole as potential anticancer agents.
    Wang HH; Qiu KM; Cui HE; Yang YS; Yin-Luo ; Xing M; Qiu XY; Bai LF; Zhu HL
    Bioorg Med Chem; 2013 Jan; 21(2):448-55. PubMed ID: 23245802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitors.
    OuYang Y; Zou W; Peng L; Yang Z; Tang Q; Chen M; Jia S; Zhang H; Lan Z; Zheng P; Zhu W
    Eur J Med Chem; 2018 Jun; 154():29-43. PubMed ID: 29775935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis and Biological Evaluation of Benzohydrazide Derivatives Containing Dihydropyrazoles as Potential EGFR Kinase Inhibitors.
    Wang HC; Yan XQ; Yan TL; Li HX; Wang ZC; Zhu HL
    Molecules; 2016 Aug; 21(8):. PubMed ID: 27527130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
    Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
    Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
    Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
    Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.
    Lv PC; Li DD; Li QS; Lu X; Xiao ZP; Zhu HL
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5374-7. PubMed ID: 21802290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors.
    Zhang HQ; Gong FH; Li CG; Zhang C; Wang YJ; Xu YG; Sun LP
    Eur J Med Chem; 2016 Feb; 109():371-9. PubMed ID: 26826581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.